SecBot SecBot
SECBOTREPLAY Home › Report › INO

INO · Inovio Pharmaceuticals (INO) is raising ~$18.3M net via a 424B5…

INOVIO PHARMACEUTICALS, INC. · 424B5 filed Jul 30, 2026 at 17:27 ET

At the news

BEARISHIMPACT 6/10

424B5 filed Jul 30, 2026 at 17:27 ET

Inovio Pharmaceuticals (INO) is raising ~$18.3M net via a 424B5 takedown from its $300M shelf, selling 21.1M shares and warrants for 42.1M shares at $0.95/unit (a ~8% discount to the $1.03 close). The company also disclosed a going-concern risk, preliminary cash of $36.7M as of June 30, 2026, and that the FDA has not yet ruled on INO-3107's accelerated approval eligibility ahead of the October 30 PDUFA date. This offering adds ~30% immediate dilution from shares alone, with potential for further dilution from the 2:1 warrant coverage.

  • Offering of 21,052,632 shares and warrants for 42,105,264 shares at $0.95/unit, raising ~$18.3M net ($20M gross)
  • Warrants exercisable at $1.10/share for 5 years; no public market expected for warrants
  • Pro forma as-adjusted net tangible book value per share of $0.58 vs. offering price of $0.95 = $0.37 immediate dilution per share
  • Company discloses 'substantial doubt exists as to our ability to continue as a going concern'

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access